指南与共识治疗药物监测与药物基因组学特殊人群用药

白消安模型引导精准给药在儿童与成人异基因造血干细胞移植中的批判性评估

Model-Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations.
指南 / 共识 · Clin Pharmacol Ther · 2025-06-22

该研究基于荷兰两家三级医院535例(0.18-72岁)患者数据,评估Bognar、Langenhorst和McCune三种白消安PK模型,目标为4天累积AUC 80-100 mg*hour/L。Bognar和Langenhorst模型准确描述浓度-时间曲线,McCune模型在<2岁儿童中低估清除率36%;基于TDM的MIPD使目标达成率从49%提升至87%。

要点

  • Bognar和Langenhorst模型在全部535例患者中准确描述白消安浓度-时间曲线。
  • McCune模型在<2岁儿童中低估清除率36%,不适用该人群。
  • 基于TDM的MIPD(第2-4天单次TDM)使目标达成率从49%升至87%。

核心结论

  • 简单PK模型如Bognar模型具有临床有效性,前提是简单性不损害性能。
  • 仅基于列线图的给药不足,TDM在优化白消安暴露中起关键作用。

研究设计与样本

  • 研究使用荷兰两家三级医院儿童和成人患者数据,最少1天、中位2天PK采样。
  • 共纳入535例患者,年龄范围0.18-72岁。
  • 评估Bognar、Langenhorst和McCune三种PK模型,并用最佳模型进行模拟以评估剂量优化和TDM作用。

主要发现

  • Bognar和Langenhorst模型数据集有重叠(模型间25%,与当前数据21%),准确描述所有535例患者浓度-时间曲线。
  • 在>60岁患者中,两模型清除率偏差和精度分别为-5.6%、6.48%和16.55%、16.95%;观测浓度偏差和精度分别为-1.86%、-6.52%和9.12%、3.58%。
  • McCune模型在<2岁儿童中低估清除率36%。
  • Langenhorst模型虽考虑年龄依赖的谷胱甘肽耗竭,但未优于更简单的Bognar模型。
  • 基于模型的初始给药未改善相对于SmPC给药的目标达成率。

关键数值与推荐

  • 白消安静脉给药目标为4天累积AUC 80-100 mg*hour/L。
  • 基于TDM的MIPD(第2-4天单次TDM)使目标达成率从49%提高到87%。
  • TDM的需治疗人数(NNT)为2.5。

临床怎么用

  • 临床可采用Bognar模型进行白消安MIPD,尤其对>60岁患者。
  • 不推荐McCune模型用于<2岁儿童。
  • 应结合TDM(第2-4天单次采样)进行剂量调整,而非仅依赖列线图或初始模型给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Busulfan is administered intravenously in conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT), with model-informed precision dosing (MIPD) targeting a 4-day cumulative AUC of 80-100 mg*hour/L. Three pharmacokinetic (PK) models-Bognar, Langenhorst, and McCune-were evaluated using data with a minimum of 1 and a median of 2 PK sampling days from pediatric and adult patients at two tertiary hospitals in the Netherlands. Simulations with the best-performing model evaluated dose optimization and the role of therapeutic drug monitoring (TDM). The Bognar and Langenhorst models, with overlapping datasets (25% between models, 21% with the current), accurately described busulfan concentration-time curves in all 535 patients (0.18-72 years), especially in those > 60 years (bias and precision in clearance; -5.6%, 6.48% and 16.55%, 16.95%; in observed concentrations -1.86%, -6.52% and 9.12%, 3.58% for both models > 60 years). The McCune model underestimated clearance by 36% in children < 2 years of age. Despite accounting for age-dependent glutathione depletion, the Langenhorst model did not outperform the simpler Bognar model. Model-based initial dosing did not improve target attainment over SmPC-based dosing. However, TDM-based MIPD with a single TDM on days 2-4 significantly improved target attainment (49% vs. 87%), with a number needed to treat for TDM of 2.5. This study demonstrates the clinical efficacy of simple PK models such as the Bognar model, providing that simplicity does not compromise performance. It highlights the inadequacy of nomogram-based dosing alone and reinforces the critical role of TDM in optimizing busulfan exposure for pediatric and adult myeloablative HSCT patients.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mahomedradja RF, Bognàr T, van Schie KE, et al. Model-Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations. Clin Pharmacol Ther. 2025. PMID: 40545743. doi:10.1002/cpt.3748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。